Literature DB >> 17038901

Kidney transplant outcomes in the indigenous population in the Northern Territory of Australia.

Natasha M Rogers1, Paul D Lawton, Matthew D Jose.   

Abstract

BACKGROUND: Indigenous Australians develop end-stage renal disease (ESRD) at a significantly higher rate than nonindigenous Australians. Renal transplantation is the preferred treatment modality; however, they are underrepresented in the transplanted population. In addition, despite the morbidity and mortality gains demonstrated in other patient groups, it is unclear whether such an advantage is replicated for indigenous Australians. We have sought to identify some of the factors that lead to poorer outcomes within this group of recipients.
METHODS: We performed a retrospective analysis of a cohort of renal transplant recipients (indigenous and nonindigenous) from the Northern Territory of Australia.
RESULTS: Indigenous patients waited longer on dialysis, were more sensitized at the time of transplantation, and the number of human leukocyte antigen mismatches was greater. Overall renal allograft survival is poorer among indigenous Australians (HR 4.13, 2.0-8.5, P<0.0001) with the majority of grafts lost due to recipient death. The most common cause of death was septicemia. Graft loss due to any cause has not been influenced by the absence of full-time specialist staff at major treatment centers. Infection rates are greatly increased in indigenous patients (RR 4.1, 95% CI 3.5-4.7, P<0.0001), in addition to the incidence of rejection (RR 2.5 95% CI 1.8-3.5, P<0.001) and hospitalization (RR 3.9, 95% CI 3.2-4.9, P<0.0001). There is increased steroid exposure among indigenous recipients.
CONCLUSIONS: Indigenous recipients of cadaveric kidney transplants have worse outcomes than nonindigenous recipients, mostly due to increased mortality and morbidity from infective causes.

Entities:  

Mesh:

Year:  2006        PMID: 17038901     DOI: 10.1097/01.tp.0000232439.88527.49

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.

Authors:  Linda A Selvey; Wai H Lim; Peter Boan; Ramyasuda Swaminathan; Claudia Slimings; Amy E Harrison; Aron Chakera
Journal:  BMC Infect Dis       Date:  2017-07-17       Impact factor: 3.090

2.  Weight change trajectories in Aboriginal and Torres Strait islander Australians after kidney transplantation: a cohort analysis using the Australia and New Zealand Dialysis and Transplant registry (ANZDATA).

Authors:  Sandawana William Majoni; Shahid Ullah; James Collett; Jaquelyne T Hughes; Stephen McDonald
Journal:  BMC Nephrol       Date:  2019-06-25       Impact factor: 2.388

3.  Study Protocol--Improving Access to Kidney Transplants (IMPAKT): a detailed account of a qualitative study investigating barriers to transplant for Australian Indigenous people with end-stage kidney disease.

Authors:  Jeannie Devitt; Alan Cass; Joan Cunningham; Cilla Preece; Kate Anderson; Paul Snelling
Journal:  BMC Health Serv Res       Date:  2008-02-04       Impact factor: 2.655

Review 4.  An expanded nationwide view of chronic kidney disease in Aboriginal Australians.

Authors:  Wendy E Hoy; Susan A Mott; Stephen P Mc Donald
Journal:  Nephrology (Carlton)       Date:  2016-11       Impact factor: 2.506

5.  Difficult conversations: Australian Indigenous patients' views on kidney transplantation.

Authors:  Jeannie Devitt; Kate Anderson; Joan Cunningham; Cilla Preece; Paul Snelling; Alan Cass
Journal:  BMC Nephrol       Date:  2017-10-11       Impact factor: 2.388

6.  Do remote dialysis services really cost more? An economic analysis of hospital and dialysis modality costs associated with dialysis services in urban, rural and remote settings.

Authors:  Gillian Gorham; Kirsten Howard; Joan Cunningham; Federica Barzi; Paul Lawton; Alan Cass
Journal:  BMC Health Serv Res       Date:  2021-06-17       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.